Dalm, Sergiu
Karssen, Adriaan M.
Meijer, Onno C.
Belanoff, Joseph K.
de Kloet, E. Ronald
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO #015.01.076)
Koninklijke Nederlandse Akademie van Wetenschappen
Article History
Received: 15 July 2018
Accepted: 18 August 2018
First Online: 1 September 2018
Compliance with Ethical Standards
:
: SD and AMK report no conflict of interest. ERdK is on the Scientific Advisory Board of the DynaCorts Group and owns stock of Corcept Therapeutics. OCM receives funding from Corcept Therapeutics. JKB is an employee of Corcept Therapeutics, which develops novel GR ligands.